Clinical trial · Observational
Real-World Data on Clinical Characteristics, Demographics, and Outcomes of Patients With Metastatic Breast Cancer in Turkey
Demographic Data and Outcomes Of Metastatic Breast Cancer Patients Treated Over The Last Decade At Tertiary Oncology Clinics In Highly Populated Cities In Turkey: A Turkish Oncology Collaborative Group Analysis
NCT04770129CI-TRIAL-00063369completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is planned as a secondary data use (SDU) study and the data collection will be performed retrospectively. Patients who presented to the participating sites with metastatic breast cancer will be defined, and patients' data will be recorded into a database.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Breast Cancer | Malignant Breast Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- Time period 2010-2014
- description
- Data from Turkish participants with metastatic breast cancer diagnosed January 2010-December 2014 will be retrospectively collected.
- label
- Time period 2015-2019
- description
- Data from Turkish participants with metastatic breast cancer diagnosed January 2015-December 2019 will be retrospectively collected.
Primary outcomes (2)
- measure
- Treatment outcome data: Overall survival (OS)
- timeFrame
- Up to 10 years
- description
- OS: it is defined as the time from the date of initial breast cancer diagnosis to the date of death due to any cause. OS data: number (%) patients receiving first-line, second-line, third-line chemotherapy
- measure
- Treatment outcome data: Progression-free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years, no upper age limit. * Must have a definite diagnosis of metastatic breast cancer at the time of initial application at any of the participating clinical centers. * Patients who were initiated their first treatment at the center where the initial mBC diagnosis was made and whose follow-up and treatment period have continued at the current center. * Patients must have signed an informed consent that allow collection of personal data and protection of patient confidentiality according to the standard procedures of each participating center. Exclusion Criteria: * Patients who were referred to the participating centers for further treatment for a second opinion.
References
Publications (0)
Data not yet available
No reference posted for this study.